日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of Duration of Outpatient Sodium Zirconium Cyclosilicate Therapy on Hyperkalemia-Related Health Care Resource Utilization: A Matched Cohort Analysis

门诊使用环硅酸锆钠治疗持续时间对高钾血症相关医疗资源利用的影响:一项匹配队列分析

Agiro, Abiy; Cook, Erin E; Greatsinger, Ali; Mu, Fan; Smith, Jess; Reichert, Emily; Colman, Ellen; Malhotra, Arun

Disease burden of ATTR amyloidosis based on the SF-36(®) health survey

基于SF-36®健康调查的ATTR淀粉样变性疾病负担

Sanchorawala, Vaishali; Greatsinger, Alexandra; Staron, Andrew; Berk, John L; Mendelson, Lisa M; Joshi, Tracy; J Burke, Natasha; Tabatabaeepour, Nadia; Smith, Jess; Signorovitch, James

Real-world avatrombopag use for immune thrombocytopenia in the United States: the REAL-AVA 2.0 multisite chart review study

美国免疫性血小板减少症患者使用阿伐曲波帕的真实世界情况:REAL-AVA 2.0 多中心图表回顾研究

Chaturvedi, Shruti; Nagalla, Srikanth; Kolodny, Scott; Oladapo, Abiola; Bernheisel, Chelsea; Swallow, Elyse; Goldschmidt, Debbie; Greatsinger, Alexandra; Ormenaj, Loren; Sareen, Sinia; Ruiz Lopez, Jorge Nicolas; Vredenburg, Michael; Levy, Moshe Yair

Hyperkalemia and the Risks of Adverse Cardiovascular Outcomes in Patients With Chronic Kidney Disease

高钾血症与慢性肾脏病患者不良心血管事件风险

Agiro, Abiy; Mu, Fan; Cook, Erin; Greatsinger, Alexandra; Chen, Jingyi; Zhao, Angela; Louden, Elaine; Colman, Ellen; Desai, Pooja; Chertow, Glenn M

Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study

门诊开始使用环硅酸锆钠治疗后肾素-血管紧张素-醛固酮系统抑制剂的剂量:GALVANIZE RAASi 真实世界证据研究

Agiro, Abiy; Greatsinger, Ali; Mu, Fan; Cook, Erin E; Chen, Jingyi; Sundar, Manasvi; Zhao, Angela; Colman, Ellen; Malhotra, Arun

Psychometric evaluation of novel hyperphagia questionnaires in a real-world setting for patients with a rare MC4R pathway disease

在真实世界环境中对患有罕见MC4R通路疾病的患者的新型过度进食问卷进行心理测量学评估

Pomeroy, Jeremy; Mallya, Usha G; Yang, Min; Huber, Caroline; Greatsinger, Alexandra; Hagopian, Ella; Haqq, Andrea M

Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?

简明语言摘要:在现实世界中,接受阿比特龙或恩扎卢胺治疗的转移性去势抵抗性前列腺癌 (mCRPC) 患者能活多久?

George, Daniel J; Ramaswamy, Krishnan; Yang, Hongbo; Liu, Qing; Zhang, Adina; Greatsinger, Alexandra; Ivanova, Jasmina; Thompson, Betty; Emir, Birol; Hong, Agnes; Freedland, Stephen J

Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study

接受恩福妥单抗治疗前,局部晚期/转移性尿路上皮癌患者的治疗模式、医疗资源利用情况和费用:一项真实世界证据研究

Morgans, Alicia K; Mucha, Lisa; Quicquaro, Christina; Shih, Vanessa; Xie, Bin; Young, Christopher; Yang, Hongbo; Liu, Qing; Greatsinger, Alexandra; Lax, Angela

Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer

在未接受化疗的转移性去势抵抗性前列腺癌患者中,醋酸阿比特龙与恩扎卢胺治疗的真实世界总生存期比较

George, Daniel J; Ramaswamy, Krishnan; Yang, Hongbo; Liu, Qing; Zhang, Adina; Greatsinger, Alexandra; Ivanova, Jasmina; Thompson, Betty; Emir, Birol; Hong, Agnes; Freedland, Stephen J

Hyperkalemia and Risk of CKD Progression: A Propensity Score-Matched Analysis

高钾血症与慢性肾脏病进展风险:倾向评分匹配分析

Agiro, Abiy; Cook, Erin; Mu, Fan; Greatsinger, Alexandra; Chen, Jingyi; Zhao, Angela; Louden, Elaine; Colman, Ellen; Desai, Pooja; Chertow, Glenn M